Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Newgreen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Neurourology and Urodynamics|April 19, 2017
The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometryNiels Klarskov, Dirk Cerneus, William Sawyer, et al.
European Journal of Pharmacology|November 23, 2007
Tolterodine does not affect memory assessed by passive-avoidance response test in miceGregg D Cappon, Brian Bush, Donald Newgreen, et al.
Birth Defects Research. Part C, Embryo Today : Reviews|September 18, 2014
The neural crest: a versatile organ systemDongcheng Zhang, Samiramis Ighaniyan, Lefteris Stathopoulos, et al.
Pharmacology Research & Perspectives|November 24, 2020
Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivityStacey Tannenbaum, Martin den Adel, Walter Krauwinkel, et al.
European Urology|October 1, 2016
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical TrialDonald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, et al.
The Journal of Urology|May 17, 2017
Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive BladderDonald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, et al.
European Urology|March 12, 2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)Paul Abrams, Con Kelleher, David Staskin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2004
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in ratsKlaas P Zuideveld, Piet H Van der Graaf, Donald Newgreen, et al.
Journal of Pediatric Urology|February 3, 2020
Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studiesIsrael Franco, Piet Hoebeke, Małgorzata Baka-Ostrowska, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Neurourology and Urodynamics|April 19, 2017
The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometryNiels Klarskov, Dirk Cerneus, William Sawyer, et al.
European Journal of Pharmacology|November 23, 2007
Tolterodine does not affect memory assessed by passive-avoidance response test in miceGregg D Cappon, Brian Bush, Donald Newgreen, et al.
Birth Defects Research. Part C, Embryo Today : Reviews|September 18, 2014
The neural crest: a versatile organ systemDongcheng Zhang, Samiramis Ighaniyan, Lefteris Stathopoulos, et al.
Pharmacology Research & Perspectives|November 24, 2020
Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivityStacey Tannenbaum, Martin den Adel, Walter Krauwinkel, et al.
European Urology|October 1, 2016
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical TrialDonald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, et al.
The Journal of Urology|May 17, 2017
Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive BladderDonald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, et al.
European Urology|March 12, 2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)Paul Abrams, Con Kelleher, David Staskin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2004
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in ratsKlaas P Zuideveld, Piet H Van der Graaf, Donald Newgreen, et al.
Journal of Pediatric Urology|February 3, 2020
Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studiesIsrael Franco, Piet Hoebeke, Małgorzata Baka-Ostrowska, et al.
Pageof 2